---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-175284"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2022-06-16T23:59:59+00:00"
generated_at: "2026-06-25T01:12:22.396589+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aileron appoints interim CFO; shareholders approve reverse stock split (1:5–1:25)

## Summary
- Susan L. Drexler appointed interim CFO effective June 16, 2022, via consulting agreement with Danforth Advisors.
- Shareholders approved reverse stock split (1:5 to 1:25) and proportional increase in authorized shares, board to set ratio by Dec 31, 2022.
- Stockholders ratified PwC as independent auditor for fiscal year 2022.
- William McKee and Nolan Sigal re-elected as Class II directors for three-year terms.

## SEC filing metadata
- accession: 0001193125-22-175284
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2022-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/0001193125-22-175284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/d256872d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-175284
- JSON: https://secwatch.observer/filing/0001193125-22-175284.json
- Plain text: https://secwatch.observer/filing/0001193125-22-175284.txt

## Key facts
- Executive change
  Susan L. Drexler was appointed as interim chief financial officer at Rein Therapeutics, Inc..
  - Action: appointed
  - Role: interim chief financial officer
  source text: On June 15, 2022, the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Susan L. Drexler, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of June 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/0001193125-22-175284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.